| BRI
has built a leading state-of-the-art infrastructure for the discovery
and development of neuro-related therapeutics derived from Chinese
medicine. Over the past few years, the Institute has successfully
carried out the following programs with support from the Innovation
and Technology Fund : |
|
|
 |
Development
of Novel Subtype-specific Agonists for Melatonin Receptors
(ITS/113/03) |
|
The
project capitalized on the Institute's discovery of novel compounds
that exhibit agonistic activity at melatonin receptor subtypes. The
lead compounds underwent detailed characterization, chemical modifications,
and structure-activity-relationships determination. |
|
|
|
Applied
Genomics for Drug Discovery
(ITS/226/01) |
|
The
project aimed to establish an applied genomic platform for the development
of an expression profiling database to facilitate the discovery and
development of neuro-related drug targets and small molecule therapeutics.
|
|
|
|
Establishing
the SimBioDas "Artifical Gut" Technologies
(UIM/036) |
|
BRI
researchers set up an ingredient profile for a selected Chinese medicine
formula for liver cancer, using both conventional analytical methods
and the SimBioDas "Artificial gut" technology developed
by the Kinetana Hong Kong Herbal Pharmaceuticals Ltd. |
|
|
|
Combinatorial
Libraries Based on Compounds of Traditional Chinese Medicine (TCM)
Origin (ITS/119/00) |
|
The
project focused on the establishment of state-of-the-art capabilities
in combinatorial chemistry and developed valuable libraries of Chinese
medicine-based combinatorial compounds. |
|
|
|
Standardization
and Certification of Chinese Medicine (ITS/173/00) |
|
BRI
was actively engaged in inter-institutional efforts to develop and
prepare guidelines for the standardisation and certification of Chinese
medicine in the form of monographs by surveying current documents
and literature. |
|
|
|
Development
of Quality Index for Sanqi (Radix Notoginseng) from Wenshan,
Yunnan
(UIM/009) |
|
Through
this project, BRI and the New World Bioscience Co. Limited collaborated
to develop a strategy using multiple approaches, namely DNA fingerprinting,
chemical analysis and biological assays, for the assurance of efficacy
and safety of Radix Notoginseng. |
|
|
|
High-Throughput
Drug Screening Center for TCM
(AF/166/99) |
|
The
project involved the build-up of an integrated high-throughput drug
screening capability to discover and identify Chinese medicine ingredients
with promising clinical and commercial potentials. |
|
|
|
Development
of Innovative Genechip Technology (AF/150/99) |
|
The
project focused on the establishment of microarray fabrication expertise
in order to produce microarray products for a number of applications
such as drug discovery and genomics research. |
|
|
|
Establishment
of a BRI TCM Center (AF/178/97) |
|
The
Center was established with the goals to facilitate the advancement
of Chinese medicine through multidisciplinary research and development
activities and services, to foster the formation of strategic partnerships,
and to provide the much needed high-technology services for the industry.
|
|
|
